Results for the substance glasdegib

Glasdegib is a Hedgehog pathway inhibitor used in the treatment of acute myeloid leukemia (AML) in patients who are not eligible for intensive chemotherapy. It works by blocking a protein essential for the survival of cancer cells.

The medication is administered orally, usually in combination with other therapies, and has shown efficacy in prolonging survival in AML patients. It is important that treatment is monitored by an oncology specialist.

Common side effects include nausea, fatigue, anemia, and decreased appetite. In rare cases, severe side effects such as QT interval prolongation may occur.

Glasdegib represents an innovative therapeutic option for AML patients, offering a treatment chance where options are limited.